ADC Bio is developing new process technology to speed, simplify and significantly lower the costs of the conjugation process to produce new antibody drug conjugate (ADC)-based anti-cancer drugs.
With surging numbers of “second generation” drugs in development (currently around 200) tumour-selective ADCs are building a significant position in the oncology field ? the fastest growing sector in healthcare. The company’s technology aims to become a new paradigm in the way ADCs are developed and manufactured, increasing accessibility for patients by helping to contain ADC production complexity and cost.
ADC Bio?s patented Lock-Release technology results in fast, simple and robust conjugation processes, with the potential to eliminate several process steps whilst enhancing product quality.
OpTIC Technium,
Ffordd William Morgan,
St Asaph Business Park,
St Asaph
Denbighshire
LL17 0JD
United Kingdom
